How AI and Genomic Testing Are Reshaping Cancer Trial Recruitment: The Massive Bio and NeoGenomics Partnership

The oncology industry is witnessing a significant shift in how patients are matched with clinical trials. Two major players—Massive Bio, an AI-driven oncology platform, and NeoGenomics, Inc. (NASDAQ: NEO), a leading cancer diagnostic laboratory—have joined forces to streamline this process and ultimately transform patient care.

The Core Partnership Model

At its heart, this collaboration harnesses the strengths of both organizations. NeoGenomics’ extensive diagnostic infrastructure and biomarker testing capabilities combine with Massive Bio’s proprietary artificial intelligence platform to create a more efficient trial matching system. The workflow is straightforward yet powerful: NeoGenomics identifies patients in real time based on biomarker status and genetic profiles, initiates physician contact, and Massive Bio then facilitates patient consent and enrollment screening. This two-stage approach eliminates traditional bottlenecks in clinical trial recruitment.

Vishal Sikri, President of NeoGenomics’ Advanced Diagnostics Division, emphasizes the efficiency gains: “Our diagnostic tools and U.S. laboratory footprint, combined with Massive Bio’s AI capabilities and concierge-level patient services, enable us to connect patients to trials faster and more efficiently, delivering better outcomes and lower costs.”

Why This Matters for the Industry

The partnership addresses a critical challenge in oncology: the gap between available clinical trials and eligible patients. By automating biomarker screening and using machine learning to optimize patient selection, both organizations can reduce the time-to-enrollment and improve data quality for pharmaceutical companies and contract research organizations.

Selin Kurnaz, PhD, CEO and co-founder of Massive Bio, frames the partnership this way: “Our mission is equipping cancer patients with the best care options. By working with NeoGenomics—an industry leader equally committed to advancing cancer research—we leverage their diagnostic expertise to rapidly identify trial-eligible patients while ensuring they make informed treatment decisions.”

Dr. Arturo Loaiza-Bonilla, Chief Medical Officer of Massive Bio, adds another dimension: “This collaboration enables personalized patient support throughout their cancer journey, advancing precision oncology and research simultaneously.”

Company Background and Scale

Massive Bio operates an AI platform serving over two dozen pharmaceutical firms, contract research organizations, and hospital networks. Founded in 2015, the company now employs nearly 100 people across 12 countries and holds an SBIR contract from the National Cancer Institute.

NeoGenomics operates CAP-accredited and CLIA-certified laboratories in eight U.S. cities (Fort Myers and Tampa, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; and Nashville, Tennessee), plus international facilities in Cambridge UK, Rolle Switzerland, and China. The company provides one of the most comprehensive oncology-focused testing menus globally, serving pathologists, oncologists, hospital systems, and pharmaceutical partners across the U.S., Europe, and Asia.

The Precision Medicine Opportunity

This partnership exemplifies the broader trend toward precision oncology—where genetic data, AI, and clinical expertise converge to optimize treatment pathways. By connecting diagnostic insights with patient-matching algorithms, both organizations position themselves at the forefront of this shift, improving access to trials for cancer patients while accelerating drug development cycles for their pharmaceutical partners.